Cellectis S.A. Announces Calyxt is New Name for its Plant Sciences Subsidiary
Published on May 05, 2015
May 4, 2015 – Paris (France) – Cellectis S.A. (Alternext: ALCLS – Nasdaq Global Market: CLLS) a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology, today announced that it has changed the name of its subsidiary, Cellectis plant sciences, Inc. to Calyxt, Inc.
The name change is part of Cellectis’ effort to further distinguish the parent company’s focus from that of it subsidiary. Gene editing is the common base of the two companies: it is used by Cellectis in the development of new and innovative product candidates for treatment of cancers, and by Calyxt in the development of improved crops for consumers with healthier characteristics. The goal of the name change is to leverage the strengths of both Cellectis and Calyxt brand identities.
To find out more about Calyxt, please visit www.calyxt.com